FDA Adverse Event Injury Summary report: N

GLUMA DESENSITIZER

MDR report key: 3314030 · Received August 20, 2013

Report

Report Number
9610902-2013-00082
Event Type
Injury
Date Received
August 20, 2013
Manufacturer
HERAEUS KULZER GMBH & CO. KG, MEDICAL DIVISION
Product Code
KLE
PMA / PMN Number
K962812
Report Source
Manufacturer report

Narratives

Additional Manufacturer Narrative · 1

AS ALLOWED BY EXEMPTION (B)(4) (THE IMPORTER) IS SUBMITTING THE REPORT ON BEHALF OF HERAEUS (B)(4) (THE MFR). ALTHOUGH WE HAVE NOT ESTABLISHED THAT THE DEVICE CAUSED OR CONTRIBUTED TO THE EVENT, WE'RE REPORTING IT TO BE COMPLIANT WITH 21 CFR PART 803 AND OUT OF AN ABUNDANCE OF CAUTION. CONCLUSIONS:THE DIRECTIONS FOR USE STATES, "PROTECT MUCOUS MEMBRANES BY USING A RUBBER DAM. MAKE SURE THAT GLUMA DESENSITIZER ONLY COMES INTO CONTACT WITH THE AREA TO BE TREATED." THE PT REPORTED THAT A RUBBER DAM WAS NOT USED. SHE DESCRIBED THE USE OF DRY ANGLES. DRY ANGLES ARE NOT PROPER ISOLATION OF TISSUE; THEREFORE, THE USER WOULD HAVE EXPOSED THE SOFT TISSUES TO THE GLUMA DESENSITIZER. IT IS ADDRESSED IN THE DIRECTIONS FOR USE THAT GLUMA DESENSITIZER IS IRRITATING TO SKIN AND CONTACT WITH SKIN SHOULD BE AVOIDED. THE DIRECTIONS ALSO STATE, "GLUMA DESENSITIZER MUST NOT BE USED IF THE PT IS ALLERGIC TO ANY INGREDIENTS CONTAINED IN GLUMA DESENSITIZER." THE DIRECTIONS FOR USE ALSO STATES THAT GLUMA DESENSITIZER IS, "HARMFUL, (B)(4). IRRITATING TO SKIN. MAY CAUSE SENSITIZATION BY SKIN CONTACT." THE DIRECTIONS FOR USE ALSO STATES THAT IF NECESSARY PRECAUTIONS CANNOT BE TAKEN THEN GLUMA DESENSITIZER MUST NOT BE USED. ADDITIONAL NARRATIVE: THE LABELING GIVES SUFFICIENT WARNING TO THE USER. THE USER REPORTEDLY DID NOT PROTECT THE PT AS DIRECTED IN THE DIRECTIONS FOR USE. DUE TO THE AFOREMENTIONED REASON, CAPA MEASURES ARE NOT RECOMMENDED.

Description of Event or Problem · 1

(B)(4).

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
404172 GLUMA DESENSITIZER KLE TOOTH RESIN BONDING AGENT KLE HERAEUS KULZER GMBH & CO. KG, MEDICAL DIVISION

Patients

Seq Age Sex Outcome Treatment
1